Applied DNA Sciences Inc (APDN)

[RodeKroet]

Wondering if Evotecs new spinoff Breakpoint Therapeutics will test/use LinearX dna...
evotec-and-venture-capital-consortium-form-breakpoint-therapeutics-gmbh-5831?utm_campaign=Press...

About DNA damage responses (“DDR”)
DNA damage responses (“DDR”) are signalling pathways by which cells sense and respond to damage that affects their DNA. Most current cancer treatments, including radiation and chemotherapy, induce DNA damage with the aim of causing cancer cell death. However, many cancer cells have genetic alterations of DDR pathways. These changes enable them to resist the effect of existing therapies. They can also make those cells exquisitely and selectively sensitive to drugs that modulate DDR pathways. Modulating DNA damage responses thus offers hope to many cancer patients: those who don’t respond to existing therapies and those who may respond but suffer greatly from side effects.



ABOUT BREAKPOINT THERAPEUTICS GMBH
Breakpoint Therapeutics is a spin-off company of Evotec SE. The company is focused on the development of several discovery projects in the area of DNA damage responses (“DDR”) initiated at Evotec. The goal is to develop first-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of therapy-resistant cancers.